• Anna Estival Instituto Catalán de Oncología, ICO, Badalona, Cataluña, España
Palabras clave: Sarcoma, historia, progreso, diagnóstico, tratamiento


Los primeros datos sobre el sarcoma aparecieron en escritos del año 1500 a.C., aunque no fue hasta el descubrimiento del microscopio cuando se empezó a progresar en su estudio y clasificación. El pilar de su tratamiento ha sido y es la cirugía, que fue evolucionando desde una escisión simple a tratamientos radicales como la amputación o la resección amplia con márgenes, reduciendo así el riesgo de recurrencia. Paralelamente a la aceptación de la preservación de extremidad, como mejor tratamiento quirúrgico fue planteando la introducción del manejo multimodal, inicialmente con radioterapia. Tanto la cirugía como la radioterapia se han visto beneficiadas por los avances en las técnicas de imagen, que han aportado un mejor conocimiento de la anatomía. La quimioterapia se introdujo en el estadio localizado con la finalidad de tratar las posibles micrometástasis, y en el escenario metastásico. No obstante, los tratamientos sistémicos tienen un recorrido histórico más corto y su progresión ha sido menor. Profundizar en la biología molecular y las diferentes sensibilidades según subtipos histológicos, podrían aportar un nuevo abanico de opciones terapéuticas.

Biografía del autor/a

Anna Estival, Instituto Catalán de Oncología, ICO, Badalona, Cataluña, España
Departamento de Oncología Médica, Sección Sarcomas, Instituto Catalán de Oncología, ICO, Badalona, Cataluña, España


1. Peltier LF. Historical note on bone and soft tissue sarcoma. J Surg Oncol. 1985;30(4):201-5.
2. Home E. A short tract on the formation of tumours. London: Longman, Hurst Rees Orme Brown & Green; 1830.
3. Ewing_J. Relation of trauma to malignant tumors. Amer J Surg. 1926;40:30-6.
4. Rous P. A Transmissible Avian Neoplasm. (Sarcoma of the Common Fowl.). J Exp Med. 1910;12(5):696-705.
5. Hardell L, Sandstrom A. Case-control study: soft-tissue sarcomas and exposure to phenoxyacetic acids or chlorophenols. Br J Cancer. 1979;39(6):711-7.
6. Sears HF. Soft tissue sarcoma: a historical overview. Semin Oncol. 1981;8(2):129-32.
7. Breasted JH, New-York Historical Society. Library. The Edwin Smith surgical papyrus. Chicago, Ill.,: The University of Chicago Press; 1930.
8. Ebbell_B. The Papyrus Ebers: the greatest Egyptian medical document. Copenhagen: Levinand Munksgaard; 1937.
9. Long ER. A history of pathology. Baltimore: Williams and Wilkins Co.; 1928.
10. Severinus MA. De abscessuum recondita natura. Naples, Beltranus; 1632.
11. Morgagni GB. The Seats and Causes of Diseases investigated by Anatomy .Translated by Benjamin Alexander. London: Millen&Cadell; 1769.
12. Hodgkin. On the Anatomical Characters of some Adventitious Structures. Med Chir Trans. 1829;15(Pt 2):265- 448.
13. Hey WMRCS. Practical Observations in Surgery, illustrated with Cases. London: Candell and Davis; 1803.
14. Wardrop J. Observations on fungus haematodes or soft cancer. Ramsay&Company, editor. Edinburgh; 1809.
15. Abernethy JMRCS. Tumor classification in Surgical Observations. London: Hurst Rees Orme & Brown Longman; 1804.
16. BoyerA. Traite des Maladies Chirurgicales et des Operationes pi Leu Conviennent. Paris:Migneret; 1814.
17. LebertH. Physiologie pathologique. Paris: JB Bailliere; 1845.
18. VirchowR. Die Krankhanften Geschwuelste. Berlin; 1863.
19. KaposiM. Idiopathisches multiples pigment-sarkom der Haut. Arch Dermatol Syphil. 1872;4:265-73.
20. Gross SW. Sarcoma of the long bones: Based upon a study of 165 cases. Am J Med Sci 1879;78:17-57.
21. Mallory FB, WrightJH. Pathological Tecnique. Philadelphia: WB Sanders; 1897.
22. BorstM. Die Lehre von den Geschwulsten, mit einem mikroskopischen Atlas. Wiesbadden: JF Bergmann; 1902.
23. Caldwell JA. Z. Extradural liposarcoma of spinal canal; clinical and pathological report. Surg Gynec and Obst. 1925;40:476-80.
24. Stout AP. Liposarcoma-the Malignant Tumor of Lipoblasts. Ann Surg. 1944;119(1):86-107.
25. Stout AP. Tumors of the musculoskeletal system in the Altlas of Tumor Pathology. Washington DC: Armed Forces Institute of Pathology; 1953.
26. Hajdu SI. Soft tissue sarcomas. Cancer. 2007;109(9):1697-704.
27. Enzinger FM, Lattes R, Torloni H. Histological typing of soft tissue tumours: Geneva, World Health Organization; 1969.
28. Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 1977;40(4):1562- 70.
29. Hajdu SI. Pathology of soft tissue tumors. Philadelphia: Lea and Febiger.London: Kimpton; 1979.
30. CodmanEA. The X-ray in surgery. En: WW K, editor. Surgery: its principles and practice. Philadelphia: WB SaundersCo; 1919.
31. Henshaw RM. Surgical advances in bone and soft tissue sarcoma: 50 years of progress. Am Soc Clin Oncol Educ Book. 2014.
32. Cantin J, McNeer GP, Chu FC, Booher RJ. The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg. 1968;168(1):47-53.
33. Atkinson L, Garvan JM, Newton NC. Behavior and Management of Soft Connective Tissue Sarcomas. Cancer. 1963;16:1552-62.
34. FergusonAB. Treatment of osteogenic sarcoma. J Bone Joint Surg. 1940;22:92-100.
35. Phemister DB. Local resection of malignant tumors of bone. AMA Arch Surg. 1951;63(6):715-7.
36. Suit HD. Sarcoma of soft tissue. CA Cancer J Clin. 1978;28(5):284-95.
37. Suit HD, Russell WO, Martin RG. Management of patients with sarcoma of soft tissue in an extremity. Cancer. 1973;31(5):1247-55.
38. Parrish FF. Treatment of bone tumors by total excision and replacement with massive autologous and homologous grafts. 1966. Clin Orthop Relat Res. 2000(373):3- 10.
39. Sugarbaker PH, Barofsky I, Rosenberg SA, Gianola FJ. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery. 1982;91(1):17-23.
40. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993(286):241-6.
41. Enneking WF. History of orthopedic oncology in the United States: progress from the past, prospects for the future. Cancer Treat Res. 2009;152:529-71.
42. McNamara JJ, Paulson DL, Kingsley WB, Urshel HC Jr. Pulmonary resection for metastatic osteosarcoma. JAMA. 1968;205(7):535-6.
43. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc. 1921;21:17-24.
44. Del Regato JA. Radiotherapy of soft-tissue sarcomas. JAMA. 1963;185:216-8.
45. LeucutiaT. Radiotherapy of sarcomas of soft parts. Radiology. 1935;25:403-15.
46. Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35(5):1478-83.
47. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305-15.
48. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-41.
49. Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S et al. Soft tissue and visceral sarcomas: ESMOEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4): iv51-iv67.
50. El-Bared N, Wong P, Wang D. Soft tissue sarcoma and radiation therapy advances, impact on toxicity. Curr Treat Options Oncol. 2015;16(5):19.
51. ColeyWB. The Treatment of Malignant, Inoperable Tumors with the Mixed Toxins of Erysipelas and Bacillus Prodigiosus. Brussels: Weissenbruch; 1914.
52. Patel SR. Fifty years of advances in sarcoma treatment: moving the needle from conventional chemotherapy to targeted therapy. Am Soc Clin Oncol Educ Book. 2014:259-62.
53. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32(1):1-8.
54. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556-60.
55. Adjuvant chemotherapy for localised resectable softtissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54.
56. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-81.
57. Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987;23(10):1477-83.
58. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870-7.
59. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21(3):317-21.
60. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B et al. Role of DTIC (NSC45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976;60(2):199-203.
61. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):2528-33.
62. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755-63.
63. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016;34(8):786-93.
64. Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-37.
65. van der Graaf WT, Blay JY, Chawla SP, Kim DW, BuiNguyen B, Casali PG et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86.
Perspectiva del diagnóstico y Tratamiento del Cancer